Premature labour precipitated by highly active antiretroviral therapy: an adverse reaction in a newly diagnosed HIV-positive patient
Jennifer Broom A B and David Sowden A
+ Author Affiliations
- Author Affiliations
A Department of Infectious Diseases, Nambour General Hospital, Nambour, Qld 4560, Australia.
B Corresponding author. Email: jenniferkbroom@gmail.com
Sexual Health 8(3) 436-438 https://doi.org/10.1071/SH10071
Submitted: 15 June 2010 Accepted: 16 January 2011 Published: 17 August 2011
Abstract
A pregnant woman was diagnosed with HIV infection at 29 weeks’ gestation. Antiretroviral therapy (ART) of lopinavir–ritonavir and zidovudine–lamivudine was initiated. Ten days later, a hypersensitivity reaction occurred, followed by preterm delivery of the infant 3 days later at 30 weeks’ gestation. Hypersensitivity reactions to ART should prompt urgent consideration of a change in ART to avoid the potential for adverse pregnancy outcomes.
Additional keywords: highly active antiretroviral therapy, pregnancy, preterm birth, zidovudine.
References
[1] Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9 6–13.| Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD1c%2Fks1ejtg%3D%3D&md5=11cbb09a772bbfaf9c6def4dd90cd311CAS |
[2] Ravizza M, Martinelli P, Bucceri A, Fiore S, Alberico S, Tamburrini E, et al Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195 913–4, author reply 916.
| Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD2s7gtVeksA%3D%3D&md5=a0c35e2cc4bb057f084866357719c0adCAS |
[3] European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14 2913–20.
| European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy.Crossref | GoogleScholarGoogle Scholar |
[4] Thorne C, Patel D, Newell ML. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18 2337–9.
| European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe.Crossref | GoogleScholarGoogle Scholar |
[5] Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21 607–15.
| Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXhvFWrsLc%3D&md5=90f52bf46edfdafc6940f72c1b4c6055CAS |
[6] Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, et al Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010; 201 1035–44.
| Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXkvVCktrk%3D&md5=6b608b376b4114978f8108a977a8772eCAS |
[7] Kennedy JD. Lung function outcome in children of premature birth. J Paediatr Child Health 1999; 35 516–21.
| Lung function outcome in children of premature birth.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3c%2FpvFWjuw%3D%3D&md5=afd6163ddb83310dc84fced9230d4761CAS |
[8] Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 1483; 125 24
[9] Baron IS, Rey-Casserly C. Extremely preterm birth outcome: a review of four decades of cognitive research. Neuropsychol Rev 2010; 20 430–52.
| Extremely preterm birth outcome: a review of four decades of cognitive research.Crossref | GoogleScholarGoogle Scholar |
[10] Giles ML, Pedrana A, Jones C, Garland S, Hellard M, Lewin SR. Antenatal screening practice for infectious diseases by general practitioners in Australia. Aust N Z J Obstet Gynaecol 2009; 49 39–44.
| Antenatal screening practice for infectious diseases by general practitioners in Australia.Crossref | GoogleScholarGoogle Scholar |
[11] Patterson KB, Leone PA, Fiscus SA, Kuruc J, McCoy SI, Wolf L, et al Frequent detection of acute HIV infection in pregnant women. AIDS 2007; 21 2303–8.
| Frequent detection of acute HIV infection in pregnant women.Crossref | GoogleScholarGoogle Scholar |
[12] Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328 1670–4.
| Cutaneous disease and drug reactions in HIV infection.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3s3lsVGgsw%3D%3D&md5=993c6d205ca2e3db6644a82811f552e2CAS |
[13] Murri R, Antinori A, Camilli G, Zannoni G, Patriarca G. Fatal toxic epidermolysis induced by zidovudine. Clin Infect Dis 1996; 23 640–1.
| 1:STN:280:DyaK2s%2FjsVWnsg%3D%3D&md5=ce2254eeba90bde8ca85db37d0cc47a4CAS |
[14] Torres RA, Lin RY, Lee M, Barr MR. Zidovudine-induced leukocytoclastic vasculitis. Arch Intern Med 1992; 152 850–1.
| Zidovudine-induced leukocytoclastic vasculitis.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK383hsFSnsg%3D%3D&md5=16b8e24e81a8539541ed0d240c33936eCAS |
[15] Wassef M, Keiser P. Hypersensitivity of zidovudine: report of a case of anaphylaxis and review of the literature. Clin Infect Dis 1995; 20 1387–9.
| 1:STN:280:DyaK2MzksFeitA%3D%3D&md5=29c8de19d1feeabe692b1ed2fd804f8fCAS |
[16] McKinley GF, Mazza DS, Grieco MH. Urticarial reaction to zidovudine. Lancet 1990; 336 384
| Urticarial reaction to zidovudine.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3czmtlSitA%3D%3D&md5=f930ac73cd5d2ee6bf0554dbc06fc95dCAS |
[17] Kim SB, Seo PJ, Baik du S, Yun SY, Kim BH, Shin JE, et al A case of severe skin eruption caused by lamivudine in a patient with chronic hepatitis B Korean J Gastroenterol 2006; 48 281–5. [in Korean].
[18] Calista D. Maculo-papular rash induced by lopinavir/ritonavir. Eur J Dermatol 2005; 15 97–8.
